Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[123I]ß-CIT SPECT Imaging in Early Parkinson's Disease (ELLDOPA)
NCT00134784Phase 2Completed
- Sponsor
- Institute for Neurodegenerative Disorders
- Start
- Apr 2000
- Primary completion
- May 2007
- Modality
- Small Molecules
01
Overview
Phase 2 trial of [123I]beta-CIT in Parkinson's disease (PD), sponsored by Institute for Neurodegenerative Disorders. Primary endpoint: Change in the Ratio of the Specific Striatal [123I]B-CIT Uptake to the Nondisplaceable Striatal [123I]B-CIT Uptake Between the Two Images at 40 weeks. Started Apr 2000; status: completed.
02
Drugs
[123I]beta-CIT
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00134784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134784.